Approval · Notice of Compliance 20025 · 2017
LUCENTIS: Notice of Compliance 20025
Issued November 3, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20025
- Date
- November 3, 2017
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Expansion of the indication: the treatment of visual impairment due to choroidal neovascularisation (cnv) secondary to ocular conditions other than amd or pm, including but not limited to angoid streaks, post-inflammatory retinochoroidopathy, central serious chorioretinopathy or idiopathic chorioretinopathy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LUCENTIS | Not yet assigned | — |
Medicinal ingredients
- RANIBIZUMAB 10 MG per ML
- RANIBIZUMAB 10 MG per VIAL